Malignant mesothelioma

Common Name(s)

Malignant mesothelioma

Malignant mesothelioma is an aggressive neoplasm of the serosal lining of the chest etiologically linked to asbestos. It is diagnosed in approximately 2,000 to 3,000 individuals annually in the United States, most of whom die within 2 years of diagnosis (summary by {6:Bott et al., 2011}). See also {614327} for a tumor predisposition syndrome that may contribute to the development of malignant mesothelioma upon asbestos exposure and is caused by germline mutation in the BAP1 gene ({603089}) on chromosome 3p21.
 

Advocacy and Support Organizations

 

Condition Specific Organizations

Following organizations serve the condition "Malignant mesothelioma" for support, advocacy or research.

Logo
Mesothelioma Applied Research Foundation

The Mesothelioma Applied Research Foundation is the nonprofit collaboration of patients and families, physicians, advocates, and researchers dedicated to eradicating the life-ending and vicious effects of mesothelioma. We believe in a cure for meso. Given the human toll of suffering the disease causes, the compassion and energy of the meso community, the moral, legal and economic aspects of asbestos, and the benefits of meso research to cancer research generally, we believe that the resources to accomplish this cure are available and must be mobilized. We seek to marshal and utilize these resources responsibly, as effectively as possible, with financial transparency and by adhering to health policy guidelines that foster ethical clinical and administrative practices, and ethical decision making to: • Offer hope and support to patients and families by educating them on the disease, helping them to obtain the most up-to-date information on treatment options and to connect with meso tr

Last Updated: 1 Mar 2013

View Details

 

General Support Organizations

Not finding the support you need? Show General Support Organizations

 
 
Top

How do you compare to others with this condition?

Privately answer questions about your health. Let resources, you select, come to you.

Anonymously share and see how your answers compare with others with this condition while privately providing key pieces of information to medical researchers, disease advocacy groups, and others ONLY YOU select to help speed up cures and better alternatives.

 
 

Advocacy and Support Organizations

 

Condition Specific Organizations

Following organizations serve the condition "Malignant mesothelioma" for support, advocacy or research.

Logo
Mesothelioma Applied Research Foundation

The Mesothelioma Applied Research Foundation is the nonprofit collaboration of patients and families, physicians, advocates, and researchers dedicated to eradicating the life-ending and vicious effects of mesothelioma. We believe in a cure for meso. Given the human toll of suffering the disease causes, the compassion and energy of the meso community, the moral, legal and economic aspects of asbestos, and the benefits of meso research to cancer research generally, we believe that the resources to accomplish this cure are available and must be mobilized. We seek to marshal and utilize these resources responsibly, as effectively as possible, with financial transparency and by adhering to health policy guidelines that foster ethical clinical and administrative practices, and ethical decision making to: • Offer hope and support to patients and families by educating them on the disease, helping them to obtain the most up-to-date information on treatment options and to connect with meso tr

http://www.curemeso.org

Last Updated: 1 Mar 2013

View Details

 

General Support Organizations

Not finding the support you need? Show General Support Organizations

 
 
 
 
Top

Scientific Literature

Articles from the PubMed Database

Research articles describe the outcome of a single study. They are the published results of original research.
The terms "Malignant mesothelioma" returned 1096 free, full-text research articles on human participants. First 3 results:

Analysis of prognostic factors of patients with malignant peritoneal mesothelioma.
 

Author(s): Wenjie Yin, Guoqi Zheng, Kunna Yang, Hui Song, Yufei Liang

Journal:

 

The study aims to find out independent prognostic factors for patients with malignant peritoneal mesothelioma (MPeM).

Last Updated: 31 Dec 1969

Go To URL
Immunohistochemical Expression of Aquaporin-1 in Fluoro-Edenite-Induced Malignant Mesothelioma: A Preliminary Report.
 

Author(s): Giuseppe Angelico, Rosario Caltabiano, Carla Loreto, Antonio Ieni, Giovanni Tuccari, Caterina Ledda, Venerando Rapisarda

Journal:

 

The immunohistochemical expression of aquaporin-1 (AQP1) in asbestos-related malignant pleural mesothelioma (MPM) is emerging as a useful prognostic indicator of improved survival. A significantly increased incidence of MPM in a small town in southern Italy was ascribed to exposure ...

Last Updated: 31 Dec 1969

Go To URL
Prognostic Impact of Inflammation-related Biomarkers on Overall Survival of Patients with Inoperable Malignant Pleural Mesothelioma.
 

Author(s): Takehiro Otoshi, Yuki Kataoka, Sawako Kaku, Reika Iki, Masataka Hirabayashi

Journal: In Vivo. ;32(2):445-450.

 

The aim of the present study was to assess the prognostic utility of the pretreatment blood neutrophil-to-lymphocyte ratio (NLR) and the C-reactive protein-to-albumin ratio (CAR) in patients with inoperable malignant pleural mesothelioma (MPM).

Last Updated: 31 Dec 1969

Go To URL

Reviews from the PubMed Database

Review articles summarize what is currently known about a disease. They discuss research previously published by others.
The terms "Malignant mesothelioma" returned 117 free, full-text review articles on human participants. First 3 results:

In Silico and In Vitro Analyses of LncRNAs as Potential Regulators in the Transition from the Epithelioid to Sarcomatoid Histotype of Malignant Pleural Mesothelioma (MPM).
 

Author(s): Anand S Singh, Richard Heery, Steven G Gray

Journal:

 

Malignant pleural mesothelioma (MPM) is a rare malignancy, with extremely poor survival rates. At present, treatment options are limited, with no second line chemotherapy for those who fail first line therapy. Extensive efforts are ongoing in a bid to characterise the underlying molecular ...

Last Updated: 31 Dec 1969

Go To URL
Heterogeneity in Immune Cell Content in Malignant Pleural Mesothelioma.
 

Author(s): Jorien Minnema-Luiting, Heleen Vroman, Joachim Aerts, Robin Cornelissen

Journal:

 

Malignant pleural mesothelioma (MPM) is a highly aggressive cancer with limited therapy options and dismal prognosis. In recent years, the role of immune cells within the tumor microenvironment (TME) has become a major area of interest. In this review, we discuss the current knowledge ...

Last Updated: 31 Dec 1969

Go To URL
Secreted and Tissue miRNAs as Diagnosis Biomarkers of Malignant Pleural Mesothelioma.
 

Author(s): Vanessa Martínez-Rivera, María Cristina Negrete-García, Federico Ávila-Moreno, Blanca Ortiz-Quintero

Journal:

 

Malignant pleural mesothelioma (MPM) is a rare but aggressive tumor that originates in the pleura, is diagnosed in advanced stages and has a poor prognosis. Accurate diagnosis of MPM is often difficult and complex, and the gold standard diagnosis test is based on qualitative analysis ...

Last Updated: 31 Dec 1969

Go To URL
 
 
Top

Clinical Trial Information This information is provided by ClinicalTrials.gov

Stereotactic Body Radiation Therapy and Avelumab Immunotherapy for Treatment of Malignant Mesothelioma
 

Status: Recruiting

Condition Summary: Malignant Mesothelioma (MPM)

 

Last Updated: 8 Aug 2018

Go to URL
IP3R Modulation by Cancer Genes in Mesothelioma
 

Status: Not yet recruiting

Condition Summary: Malignant Mesothelioma

 

Last Updated: 5 Jun 2018

Go to URL
Olaparib in People With Malignant Mesothelioma
 

Status: Recruiting

Condition Summary: Mesothelioma

 

Last Updated: 1 Aug 2018

Go to URL